Moderna says its vaccine will work against new COVID-19 variants
By
Company says it found no reduction in antibody response against UK variant
New variants have created concern that mutations may make vaccines less effective
Moderna said Monday it believes its COVID-19 vaccine will work against new variants found in Britain and South Africa, although it will test a new booster shot aimed at the South Africa variant after concluding that the antibody response could be diminished.
The company said in a press release that it found no reduction in the antibody response against the variant found in Britain. Against the variant found in South Africa, it found a reduced response but still believed its two-dose regimen would provide protection.
By Reuters Staff
4 Min Read
(Reuters) - Moderna Inc said on Monday it believes its COVID-19 vaccine protects against new variants found in Britain and South Africa, although it will test a new booster shot aimed at the South African variant after concluding the antibody response could be diminished.
The company said in a news release it found no reduction in the antibody response against the variant found in Britain. Against the South African variant, it found a reduced response but still believed its two-dose regimen would provide protection.
Moderna shares closed 12.2% higher at $147.00 on Monday.
The emergence of new variants in Britain, South Africa and Brazil has created some concern that mutations in the virus may make vaccines less effective.
Article by
Vials with a sticker reading, COVID-19 / Coronavirus vaccine / Injection only are seen in front of a displayed Moderna logo in this illustration taken October 31, 2020. (Reuters) Social Share
Moderna said on Monday it believes its coronavirus (COVID-19) vaccine protects against new variants found in Britain and South Africa, although it will test a new booster shot aimed at the South Africa variant after concluding that the antibody response could be diminished.
The company said in a press release that it found no reduction in the antibody response against the variant found in Britain. Against the variant found in South Africa, it found a reduced response but still believed its two-dose regimen would provide protection.
After Modernaâs medical miracle, some investors step back
It was briefly the most highly valued biotech stock in Massachusetts. But is the companyâs market value too lofty?
By Larry Edelman Globe Columnist,Updated January 18, 2021, 2:06 p.m.
Email to a Friend
Moderna delivered a COVID-19 vaccine in just 11 months.Greg Lovett/Associated Press
Moderna performed a miracle last year: The Cambridge biotech company, which hadnât put a product on the market since it was founded in 2010, delivered a coronavirus vaccine in just 11 months.
Investors â including company executives â were richly rewarded. The stock soared by more than 700 percent from Jan. 22, when Moderna disclosed it was working with the government to develop a COVID-19 vaccine, through Dec. 8, when the price peaked and the company briefly surpassed Vertex Pharmaceuticals as the biggest biotech in Massachusetts, by market value.
Order Reprints Print Article
Johnson & Johnson says it can make enough doses of its Covid-19 vaccine this year to inoculate almost a billion people against the virus.
That would be a massive shot in the arm to the effort to end the pandemic as long as the vaccine works. Its efficacy should become clear in just a few days.
Speaking at an industry conference on Monday,.
Close
Johnson & Johnson’s Covid-19 Vaccine Could Alter the Course of the Pandemic. Investors Will Soon Know if It Works.
Johnson & Johnson says it can make enough doses of its Covid-19 vaccine this year to inoculate almost a billion people against the virus.